| AmnioWell AF | Autologous Stem Cells | Allogeneic Stem Cells | |
|---|---|---|---|
Procedure |
Consistent recovery, processing, testing and storage. Easily administered in the doctors office. | Recovered from bone marrow aspirates, adipose tissue or peripheral blood. | Various techniques, processing, testing and infusion. May require significant patient monitoring during and after cell infusion. |
Contents |
Acellular. Contains Proteins (Cytokines, Chemokines, Growth Factors), Exosomes, Hyaluronic Acid. Available in 1.0, 2.0 & 3.0 mL Available in 1,2,3, mL |
Mesenchymal stem cells (MSCs). Additionally, cryoprotects and other preservatives that may dilute out the important functional contents. |
Mesenchymal (MSCs). Also, other preservatives that may dilute out the important functional contents. Various tissue materials with unknown effects. |
Recovery Time |
Zero down time. Importantly, patient may go back to daily activities immediately, even increased activity. |
Patients undergo the initial procedure to recover the cells, then scheduled at a later time to have the cells infused. |
Patients may have to be hospitalized and monitored during and after infusion. |
Risks |
Minimal risk (Immunopriveleged.) Thousands of treatments with no adverse reactions or side effects. |
Potential reaction to cryoprotectants. |
Potential immunity response or reaction to cryoprotectants. Unknown effects on patients. |
Safety & Compliance |
AmnioWell is recovered from C-section donors under FDA regulations 21 CFR 1271. Ongoing clinical trials are providing additional safety and efficacy profiles. |
Varies on institution |
Varies on institution |
